NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want ...

ICON Public Limited (NASDAQ:ICLR – Get Free Report)’s share price reached a new 52-week low on Thursday after Truist Financial lowered their price target on the stock from $284.00 to $262.00. Truist ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

While a federal judge has paused the funding cuts, the uncertainty has researchers concerned about the future of scientific ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The University of Pennsylvania said the funding that was at risk of being cut before a restraining order took effect supports ...

Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology ...

Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown ...

On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...

The pursuit of medical breakthroughs often relies on the diligent work of clinical research scientists. These professionals ...

Supplementing omega-3 fatty acids, nutrients in fish oil and walnuts, may help slow aging, especially if you exercise and ...

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle cell disease.